P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY

Bibliographic Details
Main Authors:	Y. Lin, T. Martin, J. G. Berdeja, A. Jakubowiak, M. Agha, A. D. Cohen, A. Deol, M. Htut, A. Lesokhin, N. C. Munshi, E. O’Donnell, C. C. Jackson, T.-M. Yeh, A. Banerjee, E. Zudaire, D. Madduri, C. Zhou, L. Pacaud, S. Z. Usmani, S. Jagannath
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846712.74284.0f

Similar Items

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Nikhil Munshi, et al.
Published: (2023-08-01)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
by: S. Zweegman, et al.
Published: (2023-05-01)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
by: K. Weisel, et al.
Published: (2022-06-01)

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

S185: CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY
by: M. E. Agha, et al.
Published: (2022-06-01)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
by: Thomas Martin, et al.
Published: (2022-02-01)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
by: Endeshaw Chekol Abebe, et al.
Published: (2022-09-01)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
by: N. van de Donk, et al.
Published: (2023-05-01)

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: A. Broijl, et al.
Published: (2023-05-01)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
by: J. Hillengass, et al.
Published: (2022-06-01)

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
by: Michel Delforge, et al.
Published: (2022-12-01)

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT
by: O. Decaux, et al.
Published: (2022-06-01)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
by: NWCJ van de Donk, et al.
Published: (2022-04-01)

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: F Gay, et al.
Published: (2022-04-01)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
by: H Einsele, et al.
Published: (2022-04-01)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
by: Liviawati S. Wu, et al.
Published: (2022-12-01)

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma
by: Shuangshuang Yang, et al.
Published: (2024-01-01)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
by: Martin Vogel, et al.
Published: (2023-05-01)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: A. Dalovisio, et al.
Published: (2022-06-01)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
by: P Rodríguez-Otero, et al.
Published: (2022-04-01)

Naval LPI radars: ways to detect their operation
by: Andreev A.Yu.
Published: (2022-10-01)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
by: Hermann Einsele, et al.
Published: (2023-08-01)

24.961 Introduction to Phonology, Fall 2002
by: Zoll, Cheryl, et al.
Published: (2002)

O IIρωτομαστορας la primera tragedia de Nikos Kazantzakis O IIρωτομαστορας Nikos Kazantzakis' first tragedy
by: OLGA OMATOS SAENZ
Published: (2009-01-01)

MAS.961 Designing Sociable Media, Spring 2001
by: Donath, Judith S.
Published: (2001)

Leadership practices inventory (LPI) : other /
by: Kouzes, James M., 1945-, et al.
Published: (1988)

Leadership practices inventory (LPI) : self /
by: Kouzes, James M., 1945-, et al.
Published: (1988)

NETWORK DEVELOPMENT OF THE PUSHCHINO RADIO ASTRONOMY OBSERVATORY OF ASC LPI
by: D. V. Dumsky, et al.
Published: (2012-11-01)

Leadership practices inventory (LPI) : trainer's manual /
by: Kouzes, James M., 1945-, et al.
Published: (1988)

Leadership practices inventory (LPI) : participant's workbook /
by: Kouzes, James M., 1945-, et al.
Published: (1997)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
by: Ross Firestone, et al.
Published: (2023-08-01)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
by: Y. Wang, et al.
Published: (2022-06-01)

Leadership practices iventory (LPI) : scoring program / [disket]
by: Kouzes, James M., 1945-
Published: (1988)

LPI Radar Waveform Recognition Based on CNN and TPOT
by: Jian Wan, et al.
Published: (2019-05-01)

Semantic learning for analysis of overlapping LPI radar signals
by: Chen, Kuiyu, et al.
Published: (2023)

Clinical significance of different atlas of intracavitary electrocardiogram for PICC localization in 961 cases
by: Hui‐Min Dong, et al.
Published: (2022-01-01)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
by: O'Reilly, MA, et al.
Published: (2024)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
by: Enver Aydilek, et al.
Published: (2023-09-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
by: C. Touzeau, et al.
Published: (2022-06-01)